Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 2/20 | 0.48 |
| ▸ | CCR1 | P32246 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16448190 | 1.00 | GAA (0.49) | GAATGM2CCR1NPC1KMT2A | |
| SCHEMBL16447215 | 0.99 | TGM2 (0.49) | GAATGM2CCR1NPC1KMT2A | |
| SCHEMBL16447214 | 0.99 | TGM2 (0.49) | GAATGM2CCR1NPC1KMT2A | |
| SCHEMBL20913184 | 0.94 | KDM1A (0.52) | NPC1KDM1AP2RY12 | |
| SCHEMBL20913183 | 0.94 | KDM1A (0.52) | NPC1KDM1AP2RY12 | |
| SCHEMBL18043477 | 0.88 | KDM1A (0.60) | TGM2KDM1A | |
| SCHEMBL16447169 | 0.88 | KDM1A (0.60) | TGM2KDM1A | |
| SCHEMBL16447393 | 0.88 | KDM1A (0.54) | TGM2CCR1NPC1KMT2AKDM1A | |
| SCHEMBL16447123 | 0.88 | KMT2A (0.50) | TGM2CCR1NPC1KMT2AALDH1A1 | |
| SCHEMBL16447391 | 0.88 | KDM1A (0.54) | TGM2CCR1NPC1KMT2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230000835-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-115397820-A | Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative tumors | 伊美格生物科学公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-4073060-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | Imago Biosciences Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20210386733-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210196711-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021118996-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20210147373-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10882835-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200095214-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10370346-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| EP-3030323-B1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190070172-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20170334873-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9790195-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| EP-3030323-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015021128-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC. (US) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386733-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM3A | GAA 2665/4885TGM2 1623/4885CCR1 4447/4885 |
| US-20210196711-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM2A | GAA 2577/4885TGM2 1712/4885CCR1 4419/4885 |
| US-20170334873-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | GAA 1725/4885TGM2 1898/4885CCR1 3829/4885 |
| US-10882835-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | GAA 1725/4885TGM2 1898/4885CCR1 3829/4885 |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | GAA 1964/4885TGM2 2067/4885CCR1 4016/4885 |
| US-10370346-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | GAA 1725/4885TGM2 1898/4885CCR1 3829/4885 |
| US-20200095214-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | GAA 1725/4885TGM2 1898/4885CCR1 3829/4885 |
| US-20190070172-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM2A | GAA 2577/4885TGM2 1712/4885CCR1 4419/4885 |
| US-20230000835-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM3A | GAA 2665/4885TGM2 1623/4885CCR1 4447/4885 |
| US-20210147373-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | GAA 1725/4885TGM2 1898/4885CCR1 3829/4885 |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | GAA 1725/4885TGM2 1898/4885CCR1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.